|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
06887 SUNSHINE PHARMA
Nominal 
37.720 -0.440 (-1.153%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 1,075,308 | -44.505% | 4,815,065 | 4,018,905 | 6,385,616 | 3,813,566 |
| Cost of Sales | (497,137) | 5.761% | (1,129,670) | (960,274) | (1,308,568) | (891,377) |
| Gross Profit | 578,171 | -60.605% | 3,685,395 | 3,058,631 | 5,077,048 | 2,922,189 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (1,036) | -- | 49 | 293 | (29) | 0 | |
| Profit / (Loss) before Taxation | (568,872) | -- | 439,564 | 141,054 | 1,385,462 | (1,479,823) | |
| Taxation | (35,126) | -56.635% | (169,530) | (116,251) | (371,584) | 63,908 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 280 | -- | 2,408 | (232,237) | (828,954) | 206,710 | |
| Others | -- | -- | -- | -- | -- | 124,582 | |
| Profit / (Loss) Attributable to Shareholders | (603,718) | 1201.958% | 272,442 | (207,434) | 184,924 | (1,084,623) | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 89,179 | -7.841% | 191,455 | 177,504 | 291,698 | 634,056 |
| Depreciation & Amortisation | -- | -- | -- | 418,044 | 419,941 | 398,674 |
| Directors' Emoluments | -- | -- | -- | 92,268 | 47,847 | 3,563 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | -109.000 | 890.909% | 56.000 | -47.000 | 44.000 | -329.000 |
| DPS (cts) | 0.000 | -- | 0.000 | -- | -- | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 2.367 | 1.135 | 3.145 | 3.521 |
| NBV per share ($) | 6.708 | -- | 7.540 | 0.597 | 0.569 | (6.397) |
| Remarks: | Real time quote last updated: 01/09/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -603,718 |
| %Change | 1201.958% |
| EPS / (LPS) | RMB -1.090 |
| NBV Per Share (¥) | RMB 6.708 |